Durvalumab vs Rituximab

## Durvalumab vs Rituximab: Overview

This comparison examines the pharmacological differences between **Durvalumab** and **Rituximab**.

## Mechanism of Action

**Durvalumab**: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

**Rituximab**: Chimeric anti-CD20 IgG1 monoclonal antibody inducing B-cell depletion via CDC, ADCC, and apoptosis.

## Pharmacokinetics

**Half-life**: Durvalumab — 17 days; Rituximab — 22 days.

## Chemical Properties

**Type**: Durvalumab — Antibody; Rituximab — Antibody.